HighVista Strategies Boosts Cytokinetics Stake by 93.6%

Institutional investor adds 64,278 shares to biopharmaceutical company's stock portfolio

Mar. 16, 2026 at 11:07am

Got story updates? Submit your updates here. ›

HighVista Strategies LLC, an investment management firm, has increased its position in Cytokinetics, Incorporated (NASDAQ:CYTK) by 93.6% during the third quarter. The fund now owns 132,930 shares of the biopharmaceutical company's stock, making it Cytokinetics' 11th largest institutional investor.

Why it matters

Cytokinetics is a late-stage biopharmaceutical company focused on developing novel small-molecule therapeutics that modulate muscle function. The increase in HighVista's stake suggests the investment firm sees significant potential in the company's drug pipeline and future growth prospects.

The details

According to a recent SEC filing, HighVista Strategies purchased an additional 64,278 shares of Cytokinetics during the third quarter, bringing its total position to 132,930 shares. This represents approximately 0.11% of Cytokinetics' outstanding shares and is valued at $7.3 million based on the stock's closing price at the end of the reporting period.

  • HighVista Strategies increased its Cytokinetics stake during the 3rd quarter of 2026.

The players

HighVista Strategies LLC

An investment management firm that has increased its position in Cytokinetics, Incorporated.

Cytokinetics, Incorporated

A late-stage biopharmaceutical company focused on developing novel small-molecule therapeutics that modulate muscle function.

Got photos? Submit your photos here. ›

The takeaway

HighVista Strategies' increased stake in Cytokinetics suggests the investment firm sees significant potential in the biopharmaceutical company's drug pipeline and future growth prospects, underscoring investor confidence in Cytokinetics' ability to develop innovative muscle-modulating therapies.